Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RN486 |
| Synonyms | |
| Therapy Description |
RN486 is a selective BTK inhibitor that inhibits proliferation of B-cells (PMID: 22228807, PMID: 31200752). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RN486 | BTK inhibitor 39 | RN486 is a selective BTK inhibitor that inhibits proliferation of B-cells (PMID: 22228807, PMID: 31200752). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK T474M BTK C481S | Advanced Solid Tumor | predicted - sensitive | RN486 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with RN486 resulted in reduced Btk activity in a cell line expressing BTK variants T474M and C481S in culture (PMID: 33526860). | 33526860 |
| BTK T474M BTK C481T | Advanced Solid Tumor | predicted - sensitive | RN486 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with RN486 resulted in reduced Btk activity in a cell line expressing BTK variants T474M and C481T in culture (PMID: 33526860). | 33526860 |
| BTK G480R | mantle cell lymphoma | resistant | RN486 | Preclinical - Cell culture | Actionable | In a preclinical study, a mantle cell lymphoma cell line developed resistance to RN486 after prolonged exposure in culture, and was subsequently found to have acquired BTK G480R (PMID: 36661329). | 36661329 |
| BTK C481T | Advanced Solid Tumor | predicted - sensitive | RN486 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with RN486 resulted in reduced Btk activity in a cell line expressing BTK C481T in culture (PMID: 33526860). | 33526860 |
| BTK C481S | Advanced Solid Tumor | predicted - sensitive | RN486 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with RN486 resulted in reduced Btk activity in a cell line expressing BTK C481S in culture (PMID: 33526860). | 33526860 |
| BTK T474I BTK C481S | Advanced Solid Tumor | predicted - sensitive | RN486 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with RN486 resulted in reduced Btk activity in a cell line expressing BTK variants T474I and C481S in culture (PMID: 33526860). | 33526860 |
| BTK V416L | mantle cell lymphoma | resistant | RN486 | Preclinical - Cell culture | Actionable | In a preclinical study, a mantle cell lymphoma cell line developed resistance to RN486 after prolonged exposure in culture, and was subsequently found to have acquired BTK V416L (PMID: 36661329). | 36661329 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST